What does ALNY do?
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Headquarters
Massachusetts, USA